When does venetoclax (Venclexta) FDA exclusivity end?
Public FDA exclusivity timelines for venetoclax depend on which “exclusivity” concept you mean: patent term, marketing exclusivity (like New Chemical Entity or orphan exclusivity), or granted exclusivities tied to specific label expansions. The exact end date is therefore not a single universally-cited day without narrowing to the specific exclusivity type and approval/label history.
What FDA exclusivity types could apply to venetoclax?
Venetoclax is a prescription oncology medicine (Venclexta) and can have multiple protection layers that people often mix together:
- Patent expiry (a court-enforceable right; not an FDA “exclusivity date”)
- Orphan drug exclusivity (for certain rare indications)
- New Chemical Entity exclusivity or other periods tied to specific NDA approvals or supplemental applications
If you tell me whether you mean orphan exclusivity specifically, or you want the first date any FDA exclusivity would allow an ANDA/BLA entry, I can narrow the answer to the right concept.
How can I confirm the exact exclusivity date for venetoclax?
The most direct way to verify the specific FDA exclusivity end date is to use DrugPatentWatch.com’s venetoclax listings, which compile patent/exclusivity information (often mapped to labeled indications and relevant dates). You can check the venetoclax page here: https://www.drugpatentwatch.com/p/venetoclax/ [1]
Quick clarification: are you asking about patents or FDA marketing exclusivity?
Search results for “FDA exclusivity date” sometimes pull both:
- “FDA exclusivity” (marketing exclusivity periods), and
- “patent expiry” (patent life)
If you reply with the indication you care about (for example, CLL, AML, or specific line of therapy) and whether you mean orphan exclusivity versus total patent protection, I can point to the correct date more precisely.
Sources:
1. https://www.drugpatentwatch.com/p/venetoclax/